Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Rediscovering Euphoria: Individual Accounts of Conquering Despondency - 2Carry Nature Inside with These Staggering Plant Decisions
- 3You finally got a doctor's appointment. Here's how to get the most out of it
- 4FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- 5Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- EU waters down plans to end new petrol and diesel car sales by 2035
- Before trips to Mars, we need better protection from cosmic rays
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- First Alert: Light snow through this evening
- Language Learning Stages: Which One Gets Your Vote?
- AfD in Brandenburg takes back suit against the intelligence service
- Volcanic eruption led to the Black Death, new research suggests
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
